Skip to main content
Trending storyHistorical stories

Orakl Oncology raises $34M Series A led by Norrsken and Singular

1 reports1 report sources5 days agoUpdate

Get up to speed on this story

AI Summary

Paris-based Orakl Oncology raised a $34 million Series A led by Norrsken VC and Singular. The company uses AI to predict cancer drug trial outcomes, and its work with Sanofi is cited as the proof point. Orakl plans to increase data generation fivefold and expand beyond colorectal and pancreatic cancers into lung and gastric cancers. New teams in the US and UK will apply its predictions to more than 10 drug programs.

AI-generated from reports · 5 days agoUpdate

Report timeline

Follow the reports to understand different sides of the story.

Nov 12
  1. Tech Funding NewsTop Deals
    Orakl Oncology raises $34M Series A to predict cancer drug trial outcomes with AI

    Paris-based Orakl Oncology raised $34M in a Series A led by Norrsken VC and Singular.

Trend for this story

Comparable range current
3
Comparable range peak
9Nov 12 23:00
Change in the last 24 hours
-49%

Trends only compare the same entities observed consistently and completely, so the scope may be smaller than the current trending statistics. Move the pointer or click the chart to view hourly trending; use the left and right arrow keys on a keyboard to switch.

Subscribe to the newsletters

Free, by email. No account needed. Pick one or both.

No spam. Unsubscribe anytime by emailing team@midu.si. Want alerts and full data? Sign up free (separate from the newsletter). Privacy.

Not investment advice. Midu summarizes public reports and SEC filings for information only. · Free API · Pricing